Cancer News and Research

Latest Cancer News and Research

Genentech, Astellas announce results of Tarceva Phase III study against advanced NSCLC

Genentech, a member of the Roche Group and Astellas Pharma US, Inc., today announced results of EURTAC, the first Phase III study with Tarceva in Western patients with a genetically distinct type of advanced non-small cell lung cancer (NSCLC).

4 Jun 2011

Researchers identify 'epigenetic fingerprints' of healthy volunteers, patients with common diseases

Until a decade, it was believed that differences between people were due solely to the existence of genetic changes, which are alterations in the sequence of our genes. The discoveries made during these last ten years show that beings with the same genetics like the twins and cloned animals may have different characteristics and disease due to epigenetic changes.

4 Jun 2011

From the legislatures: Calif. Assembly passes rate regulation bill; Wis. lawmakers vote to raise health costs for new firefighters, police

The state Assembly approved a bill Thursday that would give state regulators the power to reject or modify excessive health insurance premium increases similar to the way auto and homeowner insurance is regulated in California. Lawmakers voted 47-28 to approve the measure after Republican legislators walked off the floor in protest. AB52 now moves to the state Senate.

4 Jun 2011

Survival rates of wealthier patients with glioblastoma are longer than poorer patients

Survival rates of wealthier patients and those younger than 70 with glioblastoma, the most common and aggressive malignant brain tumor, have improved since 2000, whereas rates for those living in poorer areas and older than 70 have remained stagnant, according to an abstract being presented at the American Society of Clinical Oncology annual meeting in Chicago by Thomas Jefferson University Hospital researchers on Saturday, June 4.

4 Jun 2011

Five years after cancer treatment, many survivors still suffer symptoms

When people finish treatment for cancer, they want to bounce back to their former vital selves as quickly as possible. But a new Northwestern Medicine study -- one of the largest survivor studies ever conducted - shows many survivors still suffer moderate to severe problems with pain, fatigue, sleep, memory and concentration three to five years after treatment has ended.

4 Jun 2011

Peptide vaccine, Interleukin-2 show promise for patients with metastatic melanoma

For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2 can improve response rate and progression-free survival.

4 Jun 2011

Additional data supporting utility of PAM50 gene signature for breast cancer to be presented at ASCO 2011

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that researchers will present additional evidence for the potential utility of profiling breast cancer based on the PAM50 gene signature at the 2011 American Society of Clinical Oncology annual meeting taking place in Chicago, Illinois from June 3-7.

4 Jun 2011

Thermography is not a substitute for mammography, warns FDA

The Food and Drug Administration warns that thermography should not be used in place of mammography for breast cancer screening or diagnosis. FDA says mammography— an X-ray of the breast—is still the most effective way of detecting breast cancer in its earliest stages.

4 Jun 2011

Maryland researchers deny link between cell phone radiation and brain cancer

University of Maryland researchers in the A. James Clark School of Engineering have expressed concerns regarding the validity of recent findings announced in the Journal of the American Medical Association and a World Health Organization panel suggesting that radiation from cell phones may be carcinogenic.

4 Jun 2011

Enzyme Research journal publishes new peer-reviewed article involving Protandim

LifeVantage Corporation, the maker of Protandim, a clinically demonstrated, science-based therapy for the reduction of oxidative stress by the synergistic activation of Nrf2, announced today that a new peer-reviewed review article involving Protandim was published in the scientific journal Enzyme Research.

4 Jun 2011

Johns Hopkins researchers solve long-standing mystery of Warburg effect

It's long been known that cancer cells eat a lot of sugar to stay alive. In fact, where normal, noncancerous cells generate energy from using some sugar and a lot of oxygen, cancerous cells use virtually no oxygen and a lot of sugar.

4 Jun 2011

SBRT is effective for patients with low-to-intermediate-risk prostate cancer: Researchers

In a multicenter clinical trial, UT Southwestern Medical Center researchers have found that higher doses of stereotactic radiation therapy requiring fewer treatments are safe and effective for patients with low-to-intermediate-risk prostate cancer.

4 Jun 2011

EntreMed's ENMD-2076 Phase 2 trial data on platinum-resistant ovarian cancer presented at ASCO 2011

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the presentation of clinical data for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.

4 Jun 2011

PTEN does not reduce effectiveness of breast cancer drug, Herceptin: Study

Contrary to what many oncologists had thought, a tumor suppressor protein known as PTEN does not reduce the effectiveness of the breast cancer drug Herceptin, according to a study by Mayo Clinic and North Central Cancer Research Group investigators.

4 Jun 2011

Key findings from Phase I clinical trial of CPI-613 in AML to be presented at ASCO 2011

Cornerstone Pharmaceuticals and Wake Forest Baptist Medical Center today announced key findings from a Phase I clinical trial of Cornerstone's first-in-class cancer metabolism inhibitor drug, CPI-613 in Acute Myeloid Leukemia.

4 Jun 2011

Response Genetics' clinical approaches to improve cancer care to be presented at ASCO 2011

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today five presentations to be held during the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL from June 3 to June 7, 2011.

4 Jun 2011

Decreasing iron-storing protein expression can enhance action of brain cancer therapy: Researchers

Brain cancer therapy may be more effective if the expression of an iron-storing protein is decreased to enhance the action of therapeutic drugs on brain cancer cells, according to Penn State College of Medicine researchers.

4 Jun 2011

U of Alberta researchers win Canadian Society of Chemistry award

A one-of-a-kind Canadian research group, based in the Faculty of Medicine & Dentistry at the University of Alberta, has now won every award handed out by the Canadian Society of Chemistry for analytical and environmental chemistry.

4 Jun 2011

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Bristol-Myers Squibb Company announced today it has entered in to a clinical collaboration agreement with Roche to evaluate the utility of Bristol-Myers Squibb's CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche's investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma.

4 Jun 2011

Hospitals need to measure quality of care

Hospitals that provide quality care for young people do not always provide the same quality care for the elderly, a new study has found.

4 Jun 2011

Cancer News and Research

Latest Cancer News and Research

Genentech, Astellas announce results of Tarceva Phase III study against advanced NSCLC

Researchers identify 'epigenetic fingerprints' of healthy volunteers, patients with common diseases

From the legislatures: Calif. Assembly passes rate regulation bill; Wis. lawmakers vote to raise health costs for new firefighters, police

Survival rates of wealthier patients with glioblastoma are longer than poorer patients

Five years after cancer treatment, many survivors still suffer symptoms

Peptide vaccine, Interleukin-2 show promise for patients with metastatic melanoma

Additional data supporting utility of PAM50 gene signature for breast cancer to be presented at ASCO 2011

Thermography is not a substitute for mammography, warns FDA

Maryland researchers deny link between cell phone radiation and brain cancer

Enzyme Research journal publishes new peer-reviewed article involving Protandim

Johns Hopkins researchers solve long-standing mystery of Warburg effect

SBRT is effective for patients with low-to-intermediate-risk prostate cancer: Researchers

EntreMed's ENMD-2076 Phase 2 trial data on platinum-resistant ovarian cancer presented at ASCO 2011

PTEN does not reduce effectiveness of breast cancer drug, Herceptin: Study

Key findings from Phase I clinical trial of CPI-613 in AML to be presented at ASCO 2011

Response Genetics' clinical approaches to improve cancer care to be presented at ASCO 2011

Decreasing iron-storing protein expression can enhance action of brain cancer therapy: Researchers

U of Alberta researchers win Canadian Society of Chemistry award

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Hospitals need to measure quality of care

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in